临床肿瘤学杂志

肝细胞癌(HCC)是全球常见且我国高发的恶性肿瘤。近年来，随着晚期HCC的系统治疗研究陆续取得成功，HCC患者5年生存率有了一定的提高，但是仍有较大的提升空间。2024年度有多项大型Ⅲ期临床研究以及若干项苗头可喜的Ⅱ期研究结果数据公布，对于当前的临床实践将带来深远的影响。本文总结了2024年度关键性的肝细胞癌临床研究进展，并且进行简评，希望为临床工作者提供参考。

Objective Hepatocellular carcinoma(HCC) is a common malignant tumor in the whole world, and especially has a high incidence in China. In recent years, the 5-year survival rate has been significantly improved, due to the successful systemic therapy researches of advanced HCC. However, there is still a lot of left to be desired. In 2024, multiple results of large phase 3 clinical studies and some potential phase 2 studies have come out, which may have a profound impact on current clinical practice. This article summarized the key clinical research progress of hepatocellular carcinoma in 2024 and provided brief comments with them, hoping to serve reference for clinical workers.